Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis

Arthritis and Rheumatism

Volumn 43, Issue 12, 2000, Pages 2648-2659

  Bendele, Alison M ^a   Chlipala, Elizabeth S ^a   Scherrer, Jon ^b   Frazier, Janet ^b   Sennello, Gina ^a   Rich, William J ^b   Edwards Iii, Carl K ^b  

^a Amgen Colorado   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; FREUND ADJUVANT; HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE; ARTICLE; BONE LESION; CHONDROPATHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SLOW RELEASE FORMULATION; TREATMENT OUTCOME;

EID: 0034544946     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M     Document Type: Article

References (51)

1. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
2. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis
3. Determination of cytokines in synovial fluids: Correlation with diagnosis and histomorphological characteristics of synovial tissue
4. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis
5. Amelioration of established type II collagen-induced arthritis with anti-IL-1
6. Proteoglycan loss and subsequent replenishment in articular cartilage after a mild arthritic insult by IL-1 in mice: Impaired proteoglycan turnover in the recovery phase
7. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: Effect of in situ blocking in murine antigen- and zymosan-induced arthritis
8. Role of interleukin-1 in antigen-induced exacerbations of murine arthritis
9. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1a/β, and IL-1Ra
10. Effects of interleukin-1 receptor antagonist in a slow-release hylan vehicle on rat type II collagen arthritis
11. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data
12. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist
13. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
14. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
15. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores
16. Effects of interleukin-1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats
17. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
18. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
19. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
20. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
21. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis
22. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen arthritis in mice
23. Anti-tumor necrosis factor ameliorates joint disease in routine collagen-induced arthritis
24. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
25. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice
26. The role of tumor necrosis factor alpha and IL-1 in polymorphonuclear leukocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis
27. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type I (TNFRI)-deficient mice
28. Antiarthritic activity of soluble tumor necrosis factor receptor type I in adjuvant arthritis: Correlation of plasma levels with efficacy
29. Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats
30. Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats
31. PEGylated recombinant human soluble tumor necrosis factor receptor type I (r-Hu-sTNF-RI): A novel high-affinity TNF receptor designed for one chronic inflammatory diseases
32. Development of arthritis, periarthritis and periostitis in rats given adjuvants
33. Development of a rapid screen for detecting and differentiating immunomodulatory vs. antiinflammatory compounds in rats
34. Animal models of arthritis: Relevance to human disease
35. The pharmacokinetics of subcutaneous injections of PEGylated recombinant methionyl human soluble tumor necrosis factor-type I receptor in subjects with active rheumatoid arthritis
36. A phase 1 study of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI [p55]) in subjects with rheumatoid arthritis [abstract]
37. Role of tumor necrosis factor-α in experimental arthritis: Separate activity of interleukin 1β in chronicity and cartilage destruction
38. TNFα and IL-1β are separate targets in chronic arthritis
39. Different roles of TNFα and IL-1 in murine streptococcal cell wall arthritis
40. Major role of interleukin-1 but not tumor necrosis factor in early cartilage degradation in immune-complex arthritis in mice
41. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation
42. Interleukin 1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor the effect of cyclooxygenase inhibition
43. Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor: Synergistic action of the cytokines in the induction of inflammation and microvascular injury
44. Down regulation of the receptors for tumor necrosis factor by interleukin-1 and 4 beta-phorbol-12-myristate-13-acetate
45. Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor
46. Blocking IL-1 and TNF
47. IL-1 induces TNF in human PBMC in vitro and a circulating TNF-like activity in rabbits
48. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1β in rabbits
49. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia
50. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
51. Regulation of cytokines, cytokine inhibitors, and acute phase proteins following anti-TNF-α therapy in rheumatoid arthritis